Business Context and Reporting Period
This Form 8-K was filed by Trovagene, Inc. (not Cardiff Oncology, Inc.) on January 8, 2018. The registrant is a Delaware corporation headquartered in San Diego, CA. The filing serves as a Regulation FD disclosure regarding upcoming investor meetings.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report is a disclosure of corporate presentation materials rather than a financial statement.
Material Changes
No material financial changes or operational updates are detailed in the text of this filing. The primary event is the announcement of third-party meetings where corporate slide presentations will be distributed.
Guidance, Outlook, and Risks
- Management Commentary: Trovagene intends to conduct meetings with third parties to present its corporate slide deck.
- Legal Status of Information: The presentation materials (Exhibit 99.1) are furnished, not filed, under Section 18 of the Exchange Act. They are not subject to the liabilities of that section unless expressly incorporated by reference in another filing.
- Risks and Contingencies: No specific risks or contingencies are disclosed in this document.
Investor Verification Checklist
- Verify the correct registrant name is Trovagene, Inc., not Cardiff Oncology, Inc.
- Review the attached Exhibit 99.1 (Corporate Presentation) for actual business updates, as the 8-K text only references the existence of the presentation.
- Confirm that the presentation materials are not legally "filed" for liability purposes under Section 18 of the Exchange Act.
- Check subsequent filings for any financial data or operational milestones referenced in the presentation.